IPO - Wellgistics Health, Inc.

Form Type: 10-Q

Filing Date: 2025-05-12

Corporate Action: Ipo

Type: Update

Accession Number: 000164117225009565

Filing Summary: Wellgistics Health, Inc.'s latest quarterly report reveals significant developments related to its financial performance and corporate activities for the period ended March 31, 2025. The company's common stock began trading on the Nasdaq Capital Market under the symbol 'WGRX' on February 21, 2025, following its initial public offering (IPO) where it issued 888,889 shares at a public offering price of $4.50 per share, raising gross proceeds of $4,000,000. This IPO is part of the company’s strategy to enhance its capitalization and improve its market visibility. The financial statements indicate a net loss for the quarter of $32,430,903, attributed largely to high operating expenses of $32,041,009. The company's total assets amount to $58,063,100, while total liabilities stand at $53,584,332, resulting in stockholders' equity of $4,478,768. Moreover, significant activities included acquisitions of Wellgistics LLC and Wood Sage LLC, enhancing their market presence in the pharmaceutical sector. The company reported total revenues of $10,863,443 for the quarter, marking an operational milestone, although they incurred substantial losses primarily due to high operational expenditures.

Form Type: S-1

Filing Date: 2025-05-05

Corporate Action: Ipo

Type: New

Accession Number: 000164117225008712

Filing Summary: Wellgistics Health, Inc. filed a registration statement on Form S-1 with the SEC on May 5, 2025, related to the resale of up to 3,578,254 shares of its common stock. The filing is intended to satisfy the obligations under an Equity Purchase Agreement entered into on April 9, 2025, allowing a Selling Stockholder, Hudson Global Ventures, LLC, to purchase shares up to $50 million. The shares consist of 3,426,254 shares issued to the Selling Stockholder under the Equity Purchase Agreement and 152,000 shares issued as a commitment fee. The common stock is traded on the Nasdaq under the symbol 'WGRX', with the last reported sale price of $4.46 per share on May 2, 2025. Wellgistics Health aims to establish itself in the pharmaceuticals and healthcare services sector, albeit as a smaller reporting company and emerging growth company, benefiting from regulatory exemptions for financial reporting.

Form Type: 424B4

Filing Date: 2025-02-21

Corporate Action: Ipo

Type: New

Accession Number: 000149315225007800

Filing Summary: Wellgistics Health, Inc. is initiating a firm commitment initial public offering (IPO) of 888,889 shares of common stock at an initial price of $4.50 per share, totaling $4 million. The company has been approved to list its common stock on the Nasdaq under the symbol 'WGRX' pending issuance. The document outlines the ownership structure following the IPO, stating that company insiders will hold approximately 30.2% of the stock post-offering. Key individuals include Prashant Patel and Suren Ajjarapu, with beneficial ownership stakes of 17.5% and 12.3% respectively. This prospectus emphasizes the risks associated with investment in the stock, including challenges in integrating recent acquisitions of Wood Sage and Wellgistics LLC, and market conditions that may affect profitability. Wellgistics Health currently operates as a holding company after completing acquisitions in 2024 and maintains a flexible business model aimed at improving healthcare services access. The offering is underwritten by Craft Capital Management LLC and D. Boral Capital LLC, with an expected stock delivery date of February 24, 2025. Investors are advised to consider the detailed risks listed in the prospectus before proceeding with any investment decisions.

Form Type: CORRESP

Filing Date: 2025-02-14

Corporate Action: Ipo

Type: New

Accession Number: 000149315225006822

Filing Summary: On February 14, 2025, Wellgistics Health, Inc. submitted a request for acceleration of the effectiveness of its Registration Statement on Form S-1, Registration No. 333-280945. The company is seeking to have the registration effective by 4:30 p.m. Eastern Standard Time on the same day or as soon thereafter as possible. This request is in accordance with Rule 461 under the Securities Act of 1933. The company acknowledges its responsibilities under the Securities Act and has requested that confirmation of the event be communicated to its outside counsel at Dykema Gossett PLLC, specifically to Kate L. Bechen. The CEO, Tim Canning, signed the request, indicating the company's formal communication to the SEC regarding the acceleration of the registration process for its initial public offering.

Form Type: CORRESP

Filing Date: 2025-02-14

Corporate Action: Ipo

Type: New

Accession Number: 000149315225006827

Filing Summary: Wellgistics Health, Inc. has filed a request for the acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-280945). This request, facilitated by Craft Capital Management LLC as the representative of the underwriters, aims for the Registration Statement to be declared effective at 4:30 p.m. Eastern Time on February 14, 2025, or as soon thereafter as practicable. The undersigned from Craft Capital Management LLC, Stephen Kiront, as Chief Operating Officer, confirms compliance with the obligations under the Securities Act and the relevant rules of the Securities Exchange Act of 1934.

Form Type: S-1/A

Filing Date: 2025-01-14

Corporate Action: Ipo

Type: Update

Accession Number: 000149315225001989

Filing Summary: Wellgistics Health, Inc. is filing for an initial public offering (IPO) of 900,000 shares of its Common Stock, with an expected price range of $4.50 to $5.50 per share. The company anticipates that its Common Stock will be listed on the Nasdaq Capital Market under the ticker symbol 'WGRX', with trading expected to begin on or about January 31, 2025. The document outlines that Wellgistics Health primarily acts as a holding company with recent acquisitions of Wood Sage LLC and Wellgistics LLC, thus expanding its operational capacity across pharmaceuticals and healthcare services. It highlights Wellgistics Health's strategy to leverage common resources and integrated solutions following the acquisitions, as well as risks associated with their business model, including integration challenges and competitive pressures in the healthcare market. The registration statement is part of Amendment No. 7 to the initial S-1 filing with the SEC. Investors are urged to consider the risks detailed in the prospectus carefully before making any investment decisions.